• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Akaal Pharma to initiate phase II trial for the topical treatment of psoriasis

Akaal Pharma to initiate phase II trial for the topical treatment of psoriasis

June 17, 2015
CenterWatch Staff

Akaal Pharma, a clinical-stage biopharmaceutical company, has received approval to initiate a randomized, double-blind, placebo-controlled phase-II clinical trial of its topical drug candidate AKP-11. AKP-11 is a novel First-in-Class topical Sphingosine 1-Phosphate receptor-1 (S1P1) modulator for the treatment of mild-to-moderate plaque psoriasis in patients. Patients will be treated daily for six weeks with the topical drug AKP-11.

“We are pleased with the results of our recently completed phase I clinical trial in which our drug candidate AKP-11 has shown an excellent safety, tolerability and efficacy for treating psoriasis. We look forward to initiating our phase II clinical trial for demonstrating clinical efficacy, safety and tolerability in patients with mild-to-moderate psoriasis. This milestone advances us one step closer to our goal of providing new safer and effective treatments to physicians to help patients with psoriasis and other dermatological conditions,” said Dale Dhanoa, Ph.D., CEO of Akaal Pharma.

AKP-11 is a novel, potent and highly selective sphingosine 1-phosphate receptor-1 (S1P1) modulator undergoing clinical development for treating psoriasis, atopic dermatitis and other skin diseases. AKP-11 was found to be safe, well-tolerated and demonstrated significant efficacy in a recently completed phase I clinical trial and a intensive nonclinical drug discovery and development.

Psoriasis is an autoimmune/inflammatory skin disorder affecting more than 2% of the global population. Psoriasis is a chronic disease that requires long-term treatment. Nearly 80% of patients have mild-to-moderate psoriasis. Psoriasis is characterized by the presence of red, scaly patches that are inflamed and produce excessive skin-cells. Psoriasis is characterized by marked infiltration of leukocytes into the dermis and epidermis, oedema, vascular leak, severe hyperplasia and inflammatory cytokine up-regulation.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing